Latest From Arrevus Inc.
Already having launched several portfolio companies, Roivant goes a step further by spinning out CNS specialist Arvelle from Axovant. BI and IBM will incorporate blockchain technology in clinical trials, while AbbVie licenses multiple myeloma candidate from TeneoBio.
- Therapeutic Areas
- Infectious & Viral Diseases
- North America
- Company Type
- Parent & Subsidiaries
- Arrevus Inc.
- Senior Management
- Carl N Kraus, Chmn., Pres. & CEO
- Contact Info
2 Davis Dr.
Research Triangle Park, NC 27709
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.